×
Verastem Net Profit Margin 2011-2025 | VSTM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Verastem net profit margin from 2011 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Verastem Net Profit Margin 2011-2025 | VSTM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Verastem net profit margin from 2011 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.7B
Amgen (AMGN)
$161.5B
Gilead Sciences (GILD)
$142.5B
Vertex Pharmaceuticals (VRTX)
$123.1B
Bristol Myers Squibb (BMY)
$98.7B
GSK (GSK)
$81B
CSL (CSLLY)
$78.2B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$42.1B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$27.4B
Royalty Pharma (RPRX)
$20.3B
Biogen (BIIB)
$19.8B
Insmed (INSM)
$18.3B
Illumina (ILMN)
$15.8B
Genmab (GNMSF)
$14B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.3B
Exelixis (EXEL)
$12.3B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$10.8B
Ascendis Pharma (ASND)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Regencell Bioscience Holdings (RGC)
$8.2B
Roivant Sciences (ROIV)
$7.9B